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Summary
INTRODUCTION: In Switzerland, the first implantation of
a subcutaneous implantable cardioverter-defibrillator (S-
ICD) took place in November 2012. Up until the end of
2016, a total of 111 S-ICDs have been implanted. The aim
of this study was to summarise the experience of a tertiary
centre in Switzerland and to discuss the results in the con-
text of international registries.
METHODS: All patients in whom an S-ICD was implanted
between November 2012 and the end of December 2016
at the University Heart Centre Zurich were included in this
study. The clinical records of all patients were reviewed for
retrospective collection of baseline characteristics as well
as implantation and follow-up data.
RESULTS: A total of 37 S-ICDs were implanted. The ma-
jority of patients (81%) were male, the mean age was 47 ±
15 years. The most common underlying cardiac condition
was coronary artery disease (30%), followed by hyper-
trophic cardiomyopathy (24%), inherited channelopathies
(19%) and nonischaemic cardiomyopathy (11%). The me-
dian left ventricular ejection fraction was 44% (interquartile
range 28–61%). There were four peri-interventional com-
plications, all of which were pocket site-related. There
were no cases of systemic infection or perioperative
death. During a median follow up of 3.7 months, there
were three appropriate and successful ICD shocks (8.1%).
Two patients (5.4%) experienced a total of three inappro-
priate shocks, all due to T-wave oversensing.
CONCLUSION: This first large Swiss experience demon-
strates results consistent with available international data.
The S-ICD may hence represent an attractive alternative
to conventional transvenous ICDs for a variety of patients.
Key words: cardiomyopathy, sudden cardiac death, sub-
cutaneous ICD
Introduction
Despite improvements in medical therapy, sudden cardiac
death (SCD) remains a major cause of cardiovascular mor-
tality. To date, implantable cardioverter-defibrillators
(ICDs) represent the most effective treatment in the pre-
vention of SCD related to ventricular arrhythmias, in the
context of a previously survived event (secondary pre-
vention) as well as in patients with an increased risk for
malignant life-threatening arrhythmias (primary preven-
tion) [1–6]. Since the first ICD implantations in the early
1980s, surgical techniques, detection and discrimination
algorithms, as well as programming experience, have im-
proved considerably [3, 7–10]. Despite the proven benefit
on survival in a large proportion of patients, transvenous
ICD therapy comes with the risk of significant morbidity
[11], mainly due to the use of a transvenous lead with an
elevated risk for acute and long-term lead complications.
These include pneumothorax, cardiac perforation and elec-
trode displacement/dysfunction, as well as infection and
inappropriate therapies. Implantation-related complica-
tions were reported to be as high as 10% [12, 13], and long-
term lead failures due to abrasions or fractures over the in-
tra- and extravascular course of the lead are present in up
to 20% over 10 years [14]. The risk for device related in-
fection is continuously present with a reported prevalence
of 0.5–7% [15]. Once infected, the entire system has to
be extracted in almost all instances for a definitive cure,
again putting the patient at risk of substantial morbidity
and mortality depending on the electrode type and dwell
time [16]. Additionally, since the risk for complications in-
creases with each intervention such as generator replace-
ment, the life-time risk of transvenous ICD complications
is particularly pronounced in younger patients.
To address these shortcomings of transvenous ICDs, a to-
tally subcutaneous ICD system (S-ICD) was developed,
which was approved for use in Europe in June 2009 [17].
This device is typically placed in a pocket between the
anterior and mid-axillary line at the level of the apex of
the left ventricle, while the S-ICD electrode is tunnelled
subcutaneously from the device pocket to ≈1 cm above
the xiphoid process, and subsequently cephalad towards
the substernal notch (fig. 1) [18]. In contrast to traditional
transvenous ICDs, the S-ICD is located completely in the
extravascular (and even extrathoracic) space. Therefore,
the typical risks associated with transvenous leads such
as pneumothorax, cardiac perforation and endocarditis are
practically nonexistent or substantially reduced (such as
for system infection). Furthermore, the S-ICD lead is more
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stable and therefore less prone to dysfunction, since its de-
sign is different from that of transvenous leads [19].
In Switzerland, the first S-ICD was implanted in Novem-
ber 2012 at the University Hospital Zurich. Up until the
end of the year 2016, a total of 111 S-ICDs were implanted
in our country, 37 of these at our institution. The aim of
this study was to summarise the results of our Swiss ter-
tiary care centre and to discuss them in the context of in-
ternational data registries.
Methods
Patient population
All patients in whom an S-ICD was implanted between
November 2012 and the end of December 2016 at the Uni-
versity Heart Centre Zurich were included in this retro-
spective analysis. The implantation and clinical records of
all patients were reviewed for collection of baseline char-
acteristics and follow-up data. Baseline variables included
age, gender, body mass index, heart rate and blood pres-
sure prior to implantation, underlying cardiomyopathy, co-
morbidities such as diabetes mellitus, history of stroke,
peripheral arterial disease, chronic obstructive pulmonary
disease and arterial hypertension, risk factors such as fami-
ly history and smoking, New York Heart Association func-
tional and Canadian Cardiovascular Society class, med-
ication, laboratory results, such as kidney function, elec-
trolytes, prothrombin time international normalised ratio
(INR) and pro-B-type natriuretic peptide (pro-BNP), ECG
parameters such as QRS, PR and corrected QT interval
as well as presence of bundle-branch or fascicular block;
echocardiography results including left ventricular ejection
fraction, end-diastolic and endsystolic volumes as well as
diameters of the left ventricle, endsystolic diameter and
indexed volume of the left atrium, presence of mitral re-
gurgitation, systolic pressure gradient between right ventri-
cle and atrium, diameter of the right atrium, end-diastolic
right ventricular area and parameters of right ventricular
function such as tricuspid annular plane systolic excursion
and fractional area change. Implantation data included in-
dication, operator, positive screening vectors prior to and
during implantation, shock-test performance, duration of
implantation, use of surgical drain and discharge days af-
ter implantation. Follow-up data included complications,
heart failure hospitalisations, cardiovascular and all-cause
mortality, implantation of a circulatory assist device or
heart transplantation, number and cause of appropriate and
inappropriate shocks and finally duration of follow up.
The study was approved by the local ethics committee and
did not receive any specific extramural funding.
Screening
All patients with an indication for ICD implantation with-
out known episodes of sustained monomorphic ventricular
tachycardia, or necessity of pacing for bradycardia or re-
synchronisation therapy, as well as all patients in whom
a transvenous defibrillator had been explanted due to a
device infection, were screened for eligibility of S-ICD
therapy. For screening, the screening tool provided by the
manufacturer was used at rest (supine and seated) and, in
Figure 1: Chest X-ray of a male patient after S-ICD implantation. The generator of the S-ICD is shown on the left side of the patient together
with the electrode, which is tunnelled subcutaneously from the generator to the xiphoid area and towards the suprasternal notch.
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special cases such as Brugada syndrome, during exercise
and/or flecainide challenge. Of note, the broader screening
of Brugada patients became standard at our institution only
after a case with inappropriate shocks due to T-wave over-
sensing because of dynamic changes in T-wave morpholo-
gy that necessitated explantation of the S-ICD system (see
Results for details).
Implantation procedure
The majority of S-ICD implantations were performed by a
consultant electrophysiologist (n = 33), the remainder by
a consultant cardiac surgeon (n = 4). All procedures were
performed under general anaesthesia in an operating the-
atre or a catheterisation laboratory under standard sterile
conditions. To ensure the correct positioning of the gener-
ator and the electrode, a dummy was placed on the skin
surface under guidance of anatomical landmarks and the
position confirmed via fluoroscopy prior to the actual in-
tervention. The S-ICD implantation was performed follow-
ing the standard operating procedure [17] with the device
placed between the serratus anterior and latissimus dor-
si muscles [20]. The majority of implantations were per-
formed using the two-incision technique, tunnelling the
electrode left to the sternum from the xiphoid area towards
the substernal notch using an 11F peel-away sheath.
In the majority of cases (n = 34), a peri-procedural device
defibrillation test was performed. Ventricular fibrillation
was induced using a 50-Hz stimulation via the device. Suc-
cessful testing was defined as correct recognition and suc-
cessful termination of the ventricular arrhythmia via a 65 J
defibrillation shock. If unsuccessful, a second attempt was
made >5 minutes later with 70 J and reversed shock po-
larity. If this attempt was also ineffective, position of the
lead and the generator were checked fluoroscopically, and,
if necessary, they were repositioned and the defibrillation
test repeated afterwards.
Follow-up after implantation
All patients underwent routine follow-up including device
interrogation and a chest X-ray prior to hospital discharge.
Patients were seen in the outpatient clinic 2 to 4 weeks lat-
er. An exercise treadmill test was routinely performed 1
month after the implantation.
Statistical analysis
Statistical analysis was performed using Microsoft® Excel
for Mac (Version 15.29.1) and RStudio (Version 0.99.902).
Normality was assessed visually with histograms and
quantile-quantile-plots, as well as the Shapiro-Wilk test.
Normally distributed continuous variables are shown as
mean ± standard deviation, non-normally distributed con-
tinuous data as median (interquartile range [IQR], 1st quar-
tile – 3rd quartile) and categorical data as n (%).
Results
Baseline characteristics
Patients´ baseline characteristics are summarised in table
1. In 38 patients, a total of 37 S-ICDs were successfully
implanted. Most of the subjects (81%) were male with a
mean age of 47 ± 15 years at implantation. Approximate-
ly 60% underwent S-ICD implantation for primary pre-
vention, and three patients underwent the procedure for
an unexplained survived sudden cardiac arrest (table 2).
The most common cardiac condition (fig. 2) was coronary
artery disease (30%), followed by hypertrophic cardiomy-
opathy (24%) and channelopathies (18%). Less common
were valvular heart disease with reduced ejection fraction,
left ventricular non-compaction and arrhythmogenic right
ventricular cardiomyopathy with one case each (“Others”
in fig. 2).
Echocardiography, ECG and laboratory findings
The median left ventricular ejection fraction (LVEF) was
44% (IQR 28–61%). In nearly all patients (97%), the ECG
prior to implantation demonstrated sinus rhythm with a
Table 1: Baseline characteristics of patients undergoing S-ICD implan-
tation.
Demographic
Age, years 47 ± 15
Male 30 (81.1)
Female 7 (18.9)
Height, cm 176 ± 7
Body mass index, kg/m2 26.4 ± 4.7
Clinical
Arterial hypertension 10 (27)
Diabetes 5 (13.5)
Systolic blood pressure (mm Hg) 114 ± 16
Heart rate (bpm) 63 ± 10
Positive family history 9 (25.7)
Smoker 7 (22.6)
History of stroke 4 (10.8)
NYHA functional class
I 17 (56.7)
II 11 (36.7)
III 2 (6.7)
IV 0 (0)
Laboratory results
Creatinine, µmol/l 87.5 (71.5–104.8)
NT-proBNP, ng/l 646 (260–1872)
Potassium, mmol/l 4.1 ± 0.2
INR 1.2 (1.1–1.2)
12-lead ECG parameters
Sinus rhythm 36 (97.3)
QRS, ms 100 (90–110)
1st degree AV block 5 (13.5)
Normal ventricular conduction 31 (86.1)
QTc, ms 420 (400–450)
Echocardiography parameters
EDVi (ml/m2) 73.2 (64.3–102.3)
EF, % 43.5 (28.3–60.5)
LAVi, ml/m2 46.0 (40.3–57.5)
Medication at implantation
Amiodarone 6 (16.2)
Beta-blockers 26 (70.3)
ACE inhibitors 19 (51.4)
Oral anticoagulation 8 (21.6)
Aspirin 10 (27.0)
ADP antagonists 2 (5.7)
ACE = angiotensin converting-enzyme; ADP = adenosine diphosphate;
AV = atrioventricular; ECG = electrocardiogram; EDVi = indexed left-
ventricular end-diastolic volume; EF = left ventricular ejection fraction;
INR = international normalised ratio; LAVI = indexed left atrial volume;
NT-proBNP = N-terminal prohormone B-type natriuretic peptide; NYHA
= New York Heart Association Normally distributed continuous values
are shown as mean ± standard deviation, non-normally distributed con-
tinuous data as median (1st quartile – 3rd quartile). Categorical data
are displayed as n (%).
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narrow QRS complex (median 100 ms, IQR 90–110 ms)
and a normal median corrected QT interval (using the
Bazett’s formula) of 420 ms. Patients eligible for CRT im-
plantation according to current guidelines were excluded
from receiving an S-ICD. However, two patients in our co-
hort already had an epicardial CRT-P system in place and
subsequently underwent S-ICD implantation.
S-ICD device implantation and complications
After the first procedure in 2012, 5 additional implanta-
tions were performed in the years 2013 and 2014. In 2015,
the number of procedures increased to 7, and further to 24
in the year 2016 (fig. 3). In all except one subject the im-
plantation was successful. In spite of a positive screening,
the procedure failed in this latter patient with arrhythmo-
genic right ventricular cardiomyopathy because of insuffi-
cient R-wave sensing and concomitant P-wave oversens-
ing in all vector configurations, which persisted even with
different lead and generator positions. As a result, the de-
cision was made to switch to a transvenous ICD system
during the same intervention, which was successfully im-
planted (albeit equally with difficulties due to a severely
Table 2: Implantation data.
Indication
Primary prevention 22 (59.5)
Secondary prevention 15 (40.5)
Post transvenous lead extraction 7 (18.9)
Intraoperative positive vectors
1 of 3 0 (0)
2 of 3 15 (60)
3 of 3 10 (40)
Defibrillation test
Successful 34 (100)
1st attempt 29 (85.3)
Not performed 3 (8.1)
Surgery and complications
Duration, minutes 70 (60–80)
Haematoma 2 (5.4)
Other pocket complications 2 (5.4)
Categorical data are displayed as n (%) and non-normally distributed
continuous data as median (1st quartile – 3rd quartile).
Figure 2: Underlying cardiomyopathy / disease resulting in pa-
tients undergoing S-ICD implantation.CAD = coronary artery dis-
ease; DCM = dilated cardiomyopathy; HCM = hypertrophic car-
diomyopathy; SCD = sudden cardiac death
enlarged right atrium and extensive areas of low voltage in
the right ventricle).
Most of the initial procedures (70%) were performed in the
cardiac surgery operating theatre; since August 2016, im-
plantations were routinely performed in the electrophysi-
ology laboratory. All procedures were done under general
anaesthesia. The median duration of the procedures was 70
minutes (IQR 60–80 min).
A total of 34 patients underwent defibrillation testing
(92%). In all cases the induced ventricular arrhythmia was
detected correctly and in 85% of cases, the first defibril-
lation attempt with a shock energy of 65 J was effective.
In three patients, a second defibrillation testing with re-
versed polarity was necessary to successfully terminate the
induced arrhythmia. The generator and the defibrillation
lead had to be repositioned in one patient each, resulting in
a final successful defibrillation rate of 100%. In three pa-
tients, defibrillation testing was not performed owing to se-
vere heart failure and a perceived risk of harm outweighing
the benefit of testing.
The majority of patients could be discharged from the hos-
pital the day (46%) or 2 days after implantation (38%; fig.
4). The other subjects (16%) were in-patients for 3 or more
days and were either survivors of a sudden cardiac arrest or
were hospitalised for other reasons (e.g., acute heart fail-
ure). No implantations have been performed in an outpa-
tient setting.
Four patients experienced perioperative complications
(10.8%), which where exclusively related to the pocket
site. There were two cases of haematoma without a sig-
Figure 3: Number of S-ICD implantations from 2012 to 2016 at the
University Heart Centre Zurich, Switzerland.
Figure 4: Time to discharge after S-ICD implantation at the Uni-
versity Heart Centre Zurich, Switzerland.
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nificant drop in blood haemoglobin levels, which could
be managed conservatively. One of the patients was under
dual antiplatelet therapy with aspirin and ticagrelor, and
the other patient was taking aspirin alone. In the other two
patients, a revision of the pocket incision was necessary
because of impaired wound healing. In both subjects the
wound healed completely after local revision without the
need of further interventions.
Follow-up
The median follow-up was 3.7 months (IQR 1.7–10.1
months). The results are summarised in table 3. During this
period, three patients (8.1%) experienced a sustained ven-
tricular arrhythmia, which was correctly detected and suc-
cessfully terminated with the delivery of a single shock in
all cases (100%).
Two patients (5.4%) experienced a total of three inappro-
priate shocks (IAS) due to T-wave oversensing. In the first
patient, with Brugada syndrome, the S-ICD had to be ex-
planted since no sensing vector adjustment could avoid the
T-wave oversensing occurring exclusively during exercise-
induced QRS widening. Of note, S-ICD screening in this
patient was performed at rest without flecainide/ajmaline
testing. A conventional transvenous single-chamber ICD
was implanted. In the other S-ICD recipient, changing of
the sensing vector could avoid further IAS.
During the follow-up period, one patient (2.7%) underwent
combined heart and lung transplantation 1.5 years after the
S-ICD implantation. During the entire observation period,
no device-related infection or lead dysfunction occurred.
Discussion
The current work represents the largest clinical experience
with the S-ICD system from a tertiary care centre in
Switzerland. In our cohort of 37 patients, we observed ef-
ficacy and safety in the peri-interventional setting and dur-
ing short-term follow-up similar to reports based on inter-
national registries [21, 22].
Baseline characteristics of the patient population
The median age of our population was younger than the
average of transvenous ICD recipients in recent trials [3,
23], and the median LVEF mildly reduced. These findings
mirror those of the large S-ICD registries (EFFORTLESS
and IDE) [21, 22]; indeed, a recent pooled analysis showed
a mean LVEF of around 40% and an average age of 50.3
years [21]. It is not surprising that the S-ICD population
differs from traditional ICD recipients in being younger
and with less advanced heart failure, which is primarily
due to patient selection. These candidates more frequently
present with heart diseases other than “typical” heart fail-
Table 3: Outcome data of patients undergoing S-ICD implantation.
Patients with ICD shocks
Appropriate and successful 3 (8.1%)
Inappropriate 2 (5.4%)
Follow up
Follow-up period, months 3.2 (1.7 - 10.1)
Heart transplantation 1 (2.7%)
Heart failure hospitalisation 2 (5.4%)
Categorical variables are displayed as n (%), continuous variables are
displayed as median (1st quartile – 3rd quartile) for non-normally dis-
tributed variables.
ure, and underlying heart diseases differ from those of re-
cipients of conventional transvenous ICDs [3, 23], [21,
22]. In contrast, subjects suffering from non-ischaemic dis-
eases such as hypertrophic cardiomyopathy, inherited
channelopathies, congenital heart disease and dilated car-
diomyopathy are commonly considered candidates for an
S-ICD [21, 22]. Nevertheless, especially over the last 2
years, primary prevention implantation in patients with un-
derlying coronary artery disease has increased, similar to
the picture observed in the aforementioned international
registries.
Efficacy and safety of the S-ICD
During the follow-up period, three patients suffered from
three ventricular arrhythmia episodes (8.1%). The conver-
sion efficacy of the S-ICD was 100% with the first shock.
This is in line with data from both previous transvenous
and S-ICD analyses [22, 24–26]. A recent pooled analy-
sis from the EFFORTLESS and IDE registry demonstrated
a successful conversion rate of 98% [21]. This is of par-
ticular importance because the S-ICD population includ-
ed a younger age group with a higher prevalence of non-
ischaemic cardiomyopathies [22], which are known to be
more difficult to cardiovert.
Implantation of a conventional transvenous ICD device
carries a risk of intervention-related complications of 2 to
6% [27–29]. Similarly, short-term complications after an
S-ICD implantation in large registries occur at around 4
to 6%, and are primarily a result of pocket infection or
device erosion [21, 22]. Others include patient discom-
fort, wound haematoma and suboptimal electrode position.
We observed in our registry a slightly higher complication
rate of 10.9%, which is most likely due to the lower total
number of implanted devices and the associated “learning
curve” during the first implantations. However, only two
patients (5.5%) required a pocket revision, and no infection
occurred. Indeed, all complications were exclusively relat-
ed to the device pocket and were managed without need
of a complete system revision. This highlights a relevant
advantage of the S-ICD system: whereas the risk of com-
plications in the perioperative period may be numerically
similar to that observed with transvenous ICDs, the associ-
ated morbidity is much lower due to the absence of possi-
bly life-threatening complications like cardiac tamponade
or haemo-/pneumothorax.
In contrast to the short-term period, device-related com-
plications over the long-term are significantly higher with
transvenous ICDs and are mainly lead-related, with an
even higher impact on morbidity and mortality [19, 30].
Indeed, the electrode of conventional ICDs has been de-
scribed as the “Achilles’ heel” of the device system [14].
The S-ICD lead, in contrast, has a fundamentally different
structure with no central lumen, resulting, above every-
thing else, in a greater tensile strength. Additionally, the
subcutaneous as opposed to intracardiac location exposes
the lead to less environmental stress. Registry data from
the Netherlands confirmed the very low risk of lead mal-
functions, with only 0.8% over an observational period of
5 years (compared with 15% in the matched transvenous
ICD cohort) [19]. For this reason, the necessity of future
lead extraction is much lower with the S-ICD system, and
the extraction procedure itself far less invasive than that
of transvenous leads [16, 31]. An analysis of long-term re-
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sults, however, was not part of our current study and will
require further investigation.
A subcutaneous lead further eliminates the necessity for a
vascular access, which can be of tremendous advantage in
patients suffering from complex congenital heart disease or
in patients on haemodialysis. The entire extravascular lo-
calisation makes the system less prone to hardware-associ-
ated systemic infection and essentially eliminates the risk
of device-related endocarditis [32]. Indeed, the risk for de-
vice-associated infection in the pooled analysis of the EF-
FORTLESS and IDE registries was low at 1.7% [21]. No-
tably, all infections were exclusively local and no case of
endovascular infection with endocarditis has been docu-
mented so far.
In two patients of our cohort, an S-ICD was implanted in
the setting of a pre-existing epicardial pacemaker without
relevant interaction between the two devices. In this partic-
ular setting, the main risk consists of undersensing of ven-
tricular fibrillation by the pacemaker, resulting in “pacing”
of the ventricle and subsequent oversensing of the pace-
maker spike by the S-ICD with failure to deliver thera-
py. This is particularly problematic after shock delivery of
the S-ICD, which may lead to a “return on reset” of the
pacemaker, resulting in unipolar stimulation (which is even
more prone to oversensing by the S-ICD). Therefore, prior
to implanting such a combined system, the choice of de-
vice and pacing mode need to be carefully considered. Af-
ter implantation, bi- and unipolar pacing at maximal out-
put in all possible configurations should be performed to
ensure the absence of device-device interaction as well as
inappropriate under- and oversensing.
Since its introduction into medical practice in 2009, the
S-ICD has undergone major relevant adjustments. Cur-
rently, the third generation of devices is being implanted.
Large international registries have been published (EF-
FORTLESS and IDE), already summarising the benefit
and safety of the S-ICD. Several prospective studies, such
as PRAETORIAN, UNTOUCHED and MADIT-S-ICD,
are ongoing and will need to confirm these positive results.
Current limitations of the S-ICD system
Since there is no direct contact between the S-ICD lead and
myocardium, the S-ICD lacks functionality for bradycardia
pacing (except for limited transthoracic post-shock pac-
ing). Therefore, in patients with a requirement for demand
pacing (e.g., atrioventricular block [AVB] or sinus brady-
cardia), a conventional transvenous ICD system is the pre-
ferred option. None of our patients presented with higher
degree (>1st degree) AVB, and only 13.5% with 1st degree
AVB. In this context, it is reassuring that only a minority
(5 to 10%) of patients qualifying for an ICD will develop
the need for pacing over time [1, 33, 34]. In turn, however,
some patients may develop an indication for an ICD when
a pacemaker has been implanted in the past. Limited da-
ta from case series show that the concurrent use of an S-
ICD and a previously implanted pacemaker, transvenous,
epicardial or even leadless, is possible [35–37]. Closely re-
lated to the lack of antibradycardia pacing is the inabili-
ty of the S-ICD to offer cardiac resynchronisation therapy
(CRT), and patients suffering from advanced systolic heart
failure with a wide QRS complex are not suitable candi-
dates for this system. Reflecting this limitation, the QRS
duration in our cohort was short (median 100 ms).
Finally, the S-ICD is unable to deliver antitachycardia pac-
ing; therefore, patients presenting with monomorphic ven-
tricular arrhythmias, which are potentially treatable via
overdrive pacing, are not ideal candidates for an S-ICD.
Several studies have demonstrated the benefit and high
success rate of antitachycardia pacing in patients with a
transvenous-ICD [38, 39]. In a primary prevention setting,
however, data from the SCD-HeFT trial demonstrated that
the annual likelihood over 3 years to require antitachycar-
dia pacing is only 1.8% [40], which is in line with the
results from the MADIT-RIT study showing that delayed
treatment for ventricular arrhythmias reduces the amount
of “appropriate” antitachycardia pacing from 15 to 3% per
year [3]. [22, 26].
Inappropriate shocks
Inappropriate shocks (IASs) are a rare, but serious problem
in ICD recipients, resulting from delivery of ICD treatment
in the absence of a life-threatening arrhythmia. Indeed,
IASs have been shown to not only be associated with psy-
chological distress and reduced quality of life [41], but al-
so with an increase in mortality [42]. The IAS rate in con-
ventional transvenous ICD registries and trials has varied
between 4 and 18% in the past [43–47], but may be as
low as 2.8 to 3.7% over 2 years with modern-type devices
and programming [10]. During the initial experience with
the S-ICD, the IAS rate was high, with a risk of 5 to 25%
[17, 48–50]. IASs in S-ICDs typically result from over-
sensing of cardiac signals (e.g., T-wave oversensing), due
to supraventricular tachycardias misinterpreted as ventric-
ular arrhythmias, or due to noncardiac oversensing (e.g.,
myopotentials). Since the electrical cardiac activation used
for the S-ICD analysis is not a true local bipolar but rather
a “farfield” signal, the system is potentially more prone to
oversensing of non-QRS signals such as the T-wave.
With technical advances such as introduction of the suture
sleeve to avoid lead migration and algorithm improve-
ments such as introduction of the INSIGHT discrimination
algorithm, the risk of IAS has been reduced to an annual
rate of 7 to 10% [21, 22]. Furthermore, current nominal de-
vice settings include a conditional zone with supraventric-
ular tachycardia discrimination and a shock zone for high
ventricular rates >220 bpm. The incidence of T-wave over-
sensing has been reduced with the introduction of pre-im-
plant electrocardiographic screening [51]. Additionally, a
software feature has been designed (SMART Pass Tech-
nology) to further minimise oversensing while maintaining
appropriate detection of the ventricular arrhythmia. A
modelled analysis of IAS episodes from the EFFORTLESS
registry demonstrated that T-wave oversensing could
thereby be reduced by 71% and the rate of IAS could be
reduced to 3.8% (L Boersma et al., presented at HRS meet-
ing 2015), which is within the range of most recent trans-
venous ICDs [3, 10, 23]. In line with these findings, two
patients (5.4%) of our cohort experienced a total of three
IASs, all of them due to T-wave oversensing.
Limitations of our current study
Limitations of our current work include its retrospective
nature, potential selection bias due to inclusion of patients
only from a large referral centre, and lack of long-term out-
come data. Further limitations include the lack of data on
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all screened patients, number of rejected patients and rea-
sons for rejection.
Conclusions and perspectives
Since its introduction in Switzerland in the year 2012, the
number of S-ICD implantations has steadily increased. Our
data, in line with large international registries, demonstrate
that the S-ICD may represent an attractive alternative to
conventional transvenous ICDs for a relevant number of
ICD candidates, offering efficacy similar to transvenous-
ICDs with similar or even fewer long-term complications.
The only exception to this is a slightly higher rate of peri-
operative complications in our cohort, probably resulting
from individual operator learning curves.
Although the S-ICD system still has some shortcomings,
simple measures can help to improve the care of S-ICD pa-
tients. For example, dual zone programming (with a high-
rate and a conditional zone) should be the standard of care;
in patients with Brugada syndrome, screening should be
performed not only at rest but also during exercise or Class
I antiarrhythmic drug challenge, to assure that dynamic
changes in QRS- and/or T-wave morphology do not lead
to inappropriate shocks [52]; and implantations should be
concentrated in experienced centres with a high volume of
procedures per operator to minimise perioperative compli-
cations [53]. Furthermore, experienced support with fol-
low-up and trouble-shooting should be provided to office-
based cardiologists to ensure optimal programming.
To summarise, with increasing experience, optimised pro-
gramming as well as new device algorithms and filters, the
S-ICD is becoming increasingly safe and may represent
an attractive alternative to transvenous ICDs for a growing
number of ICD candidates. Further studies are necessary
(and largely ongoing) comparing the S-ICD to transvenous
systems regarding hard clinical endpoints.
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